Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.

Pathare A, Al Khabori M, Alkindi S, Al Zadjali S, Misquith R, Khan H, Lapoumeroulie C, Paldi A, Krishnamoorthy R.

J Hum Genet. 2012 Oct;57(10):665-9. doi: 10.1038/jhg.2012.94. Epub 2012 Aug 2.

PMID:
22854539
2.

Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.

Daly AK.

Arch Toxicol. 2013 Mar;87(3):407-20. doi: 10.1007/s00204-013-1013-9. Epub 2013 Feb 2. Review.

PMID:
23376975
3.

Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Stehle S, Kirchheiner J, Lazar A, Fuhr U.

Clin Pharmacokinet. 2008;47(9):565-94. Review.

PMID:
18698879
4.

The pharmacogenetics of the response to warfarin in Chinese.

Lam MP, Cheung BM.

Br J Clin Pharmacol. 2012 Mar;73(3):340-7. doi: 10.1111/j.1365-2125.2011.04097.x. Review.

5.

Warfarin pharmacogenetics: does more accurate dosing benefit patients?

Eby C.

Semin Thromb Hemost. 2012 Oct;38(7):661-6. doi: 10.1055/s-0032-1326789. Epub 2012 Oct 9. Review.

6.

Pharmacogenetics of warfarin: challenges and opportunities.

Lee MT, Klein TE.

J Hum Genet. 2013 Jun;58(6):334-8. doi: 10.1038/jhg.2013.40. Epub 2013 May 9. Review.

7.

The future of warfarin pharmacogenetics in under-represented minority groups.

Cavallari LH, Perera MA.

Future Cardiol. 2012 Jul;8(4):563-76. doi: 10.2217/fca.12.31. Review.

8.

Pharmacogenetics-based warfarin dosing in children.

Hamberg AK, Wadelius M.

Pharmacogenomics. 2014 Feb;15(3):361-74. doi: 10.2217/pgs.14.8. Review.

9.

Using pharmacogenetics in real time to guide warfarin initiation: a clinician update.

Carlquist JF, Anderson JL.

Circulation. 2011 Dec 6;124(23):2554-9. doi: 10.1161/CIRCULATIONAHA.111.019737. Review. No abstract available.

10.

Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.

Danese E, Montagnana M, Johnson JA, Rettie AE, Zambon CF, Lubitz SA, Suarez-Kurtz G, Cavallari LH, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen MK, Borgiani P, Ciccacci C, Au NT, Langaee T, Siguret V, Loriot MA, Sagreiya H, Altman RB, Shahin MH, Scott SA, Khalifa SI, Chowbay B, Suriapranata IM, Teichert M, Stricker BH, Taljaard M, Botton MR, Zhang JE, Pirmohamed M, Zhang X, Carlquist JF, Horne BD, Lee MT, Pengo V, Guidi GC, Minuz P, Fava C.

Clin Pharmacol Ther. 2012 Dec;92(6):746-56. doi: 10.1038/clpt.2012.184. Epub 2012 Nov 7. Review.

11.

Implementing genotype-guided antithrombotic therapy.

Seip RL, Duconge J, RuaƱo G.

Future Cardiol. 2010 May;6(3):409-24. doi: 10.2217/fca.10.6. Review.

12.

Impact of VKORC1 gene polymorphisms on warfarin maintenance dosage: A novel systematic review and meta-analysis of 53 studies.

Tang W, Shi QP, Ding F, Yu ML, Hua J, Wang YX.

Int J Clin Pharmacol Ther. 2017 Apr;55(4):304-321. doi: 10.5414/CP202833. Review.

PMID:
28025970
13.

Expanding role of pharmacogenomics in the management of cardiovascular disorders.

Yip VL, Pirmohamed M.

Am J Cardiovasc Drugs. 2013 Jun;13(3):151-62. doi: 10.1007/s40256-013-0024-5. Review.

PMID:
23579966
14.

Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis.

Zhang J, Chen Z, Chen C.

Meta Gene. 2016 Jul 5;9:197-209. doi: 10.1016/j.mgene.2016.07.002. eCollection 2016 Sep. Review.

15.

The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review.

Bader LA, Elewa H.

PLoS One. 2016 Dec 19;11(12):e0168732. doi: 10.1371/journal.pone.0168732. eCollection 2016. Review.

16.

Pharmacogenetics and cardiovascular disease--implications for personalized medicine.

Johnson JA, Cavallari LH.

Pharmacol Rev. 2013 May 17;65(3):987-1009. doi: 10.1124/pr.112.007252. Print 2013 Jul. Review.

17.

Genotype-guided coumarin dosing: where are we now and where do we need to go next?

Baranova EV, Verhoef TI, Asselbergs FW, de Boer A, Maitland-van der Zee AH.

Expert Opin Drug Metab Toxicol. 2015 Apr;11(4):509-22. doi: 10.1517/17425255.2015.1004053. Epub 2015 Jan 16. Review.

PMID:
25595525
18.

Clinical application of cardiovascular pharmacogenetics.

Voora D, Ginsburg GS.

J Am Coll Cardiol. 2012 Jul 3;60(1):9-20. doi: 10.1016/j.jacc.2012.01.067. Review.

19.

Clinical applicability of sequence variations in genes related to drug metabolism.

Stojiljkovic M, Patrinos GP, Pavlovic S.

Curr Drug Metab. 2011 Jun;12(5):445-54. Review.

PMID:
21453274
20.

Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis.

Yu WY, Sun X, Wadelius M, Huang L, Peng C, Ma WL, Yang GP.

Cardiovasc Ther. 2016 Oct;34(5):297-307. doi: 10.1111/1755-5922.12186. Review.

PMID:
27062534

Supplemental Content

Support Center